Study Design and Statistical Analysis: An Appraisal of the Evidence

1. Explain general biostatistical principles.
2. Apply pertinent biostatistics to the evaluation of available clinical evidence with oral anticoagulants.
3. Analyze aspects of different types of relevant study designs.
4. Compare the design and analytic differences between studies or oral anticoagulants.

Non-Vitamin K Antagonist Oral Anticoagulants: Current Evidence and Place in Therapy

1. Appraise the evidence-based risks and benefits of the available oral anticoagulant therapies for venous thromboembolism (VTE) prophylaxis, VTE treatment, and atrial fibrillation.
2. Evaluate the pharmacokinetic and pharmacodynamic characteristics influencing the selection and dosing of the oral anticoagulants.
3. Develop a systematic approach to selecting anticoagulant therapy according to patient-specific factors.

Warfarin: Controversies Surrounding Pharmacogenomic Guided Dosing

1. Define patient-related characteristics that influence warfarin dose requirements.
2. Estimate the effects of genotype on warfarin pharmacokinetics and pharmacodynamics.
3. Formulate an optimal warfarin dosing strategy according to patient demographics, clinical factors, and genotype.
4. Develop and defend your stance (for vs. against) on genotype-guided therapy (for individual patient vs. population at large).
5. Formulate your opinion on what additional evidence is needed to better define the clinical utility of genotype-guided warfarin dosing.
6. Discuss barriers to implementing genotype-guided therapy.

Anticoagulation Clinics and Practice

1. Compare established and emerging anticoagulation management service (AMS) models, including the limitations involved in implementing each model.
2. Explain the characteristics of a high-performing anticoagulation clinic and the mechanisms to incorporate such characteristics into practice.
3. Establish billing practices that align with Medicare rules for reimbursement and cost justification for AMSs.